AMASA is a Boston-based, privately held early stage biotechnology company engaged in the development of novel biological cancer products with a primary focus on engineered allogenic receptor-targeted, cell-based therapeutics to eradicate tumors. Founded upon the pioneering research of Dr. Khalid Shah, Associate Professor at Harvard Medical School and Director of the Center for Stem Cell Therapeutics and Imaging, the innovative Amasa pipeline lends itself to a broad range of novel therapeutic applications intended to positively impact cancer outcomes.
Following regulatory approval, Amasa aims to initiate the clinical development stage of testing its proprietary bioengineered cells in humans, ultimately charting a path toward future commercial use in patient care. Clinical application of the Amasa platform would initially address significant unmet medical need in brain tumors (Glioblastoma). Amasa’s engineered cells are meant to be deployed as an adjuvant therapy following standard-of-care tumor resection. Proof-of-concept has been well established with this technology in mouse models, showing residual tumor eradication and increased survival.
Amasa Leadership
Advisory Board
